Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones

Black Diamond Therapeutics, Inc.

Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.
Servier will lead global development and commercialization of BDTX-4933 in RAF/RAS-mutant solid tumors, including NSCLC.
BDTX-4933 is a Phase 1 small molecule designed to target RAS mutations and RAF alterations with best-in-class potential.
Black Diamond continues to advance its MasterKey platform; deal provides non-dilutive capital to support pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.